China Health Group Inc.
8225.HKHKSEHealthcareMedical - Pharmaceuticals
Latest quote
HK$0.081
HK$0.00 · 0.00%
8225.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteChina Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research and promotion, rehabilitation tourism, and specialty hospital services, as well as Wanquan cloud health services. In addition, the company offers pharmacodynamics and clinical research of drugs. China Health Group Inc. was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. The company was founded in 1998 and is headquartered in Beijing, China.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Zhuang Xiangsong
- Listed since
- Jul 10, 2003
- Employees
- 32
Market position
52-week range
Current HK$0.081
- Open
- HK$0.081
- Previous close
- HK$0.081
- Volume
- 2.14M
- 22.29× average
- Average volume
- 96K
- Average daily volume
- Market cap
- 80.62M HKD
- Beta
- -0.42
- Market reference 1
- 50-day average
- HK$0.0901
- -10.06% below average
- 200-day average
- HK$0.1273
- -36.37% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 107.09M CNY
- P/E (TTM)
- -2.62×
- P/B (TTM)
- 1.25×
- P/S (TTM)
- 2.16×
- EV / EBITDA
- -7.62×
- Earnings yield
- -11.17%
- Free cash flow yield
- 6.91%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 55.06%
- Operating margin
- 12.15%
- Net margin
- -45.66%
- Return on equity
- -26.30%
- Return on assets
- -16.73%
- Return on invested capital
- -26.39%
Financial health
- Debt / equity
- 0×
- Current ratio
- 2.17×
- Altman Z-score
- 0.73
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 27.82M CNY | 26.45M CNY | 21.43M CNY | 13.09M CNY | 83.6M CNY |
| Cost of goods sold | 11.86M CNY | 16.39M CNY | 13.21M CNY | 7.35M CNY | 19.74M CNY |
| Gross profit | 15.97M CNY | 10.07M CNY | 8.21M CNY | 5.74M CNY | 63.86M CNY |
| Selling, general, and administrative | 30.42M CNY | 24.88M CNY | 65.54M CNY | 13.97M CNY | 14.43M CNY |
| Operating expenses | 30.42M CNY | 24.91M CNY | 65.54M CNY | 21.8M CNY | 21.77M CNY |
| Interest income | 68.19K CNY | 63K CNY | 116K CNY | 202K CNY | 430K CNY |
| Interest expense | — | — | — | 17K CNY | 15K CNY |
| Depreciation and amortization | 406.21K CNY | 606K CNY | 234K CNY | 151K CNY | 201K CNY |
| Operating income | −14.45M CNY | −14.85M CNY | −57.33M CNY | −16.06M CNY | 42.09M CNY |
| Net income | −14.57M CNY | −14.52M CNY | −58.01M CNY | −15.84M CNY | 36.33M CNY |
Company facts updated Aug 25, 2026.
Earnings
- Latest EPS result
- -0.01
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Apr 7, 2004 | HK$0.005Irregular | Apr 13, 2004 | May 14, 2004 |
Ex-dividend Apr 7, 2004
HK$0.005
Irregular
Record Apr 13, 2004 · Payment May 14, 2004
8225.HK peers
Continue in GoAI
Research 8225.HKresearch.disclaimer